Prednisone: Participant randomization to receive shortened (8 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
Prednisone: Participant randomization to receive standard (26 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
Study summary
The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis
* with tocilizumab,
* while using less cortisone.
Eligibility
Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients diagnosed with giant cell arteritis
* Start of tocilizumab treatment at baseline as part of routine clinical practice
* Receive ≥ 20 mg/day prednisone (or equivalent) at baseline
* Written informed consent
Exclusion Criteria:
* Treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) prior to the first dose of tocilizumab.
Primary outcome measure(s)
Absence of a major relapse from randomization to 52 weeks — 52 weeks Composite endpoint. Pairwise comparisons of each patient from the control arm with each patient of the experimental arm.
Cumulative glucocorticoid exposure from randomization to 52 weeks — 52 weeks Composite endpoint. Pairwise comparisons of each patient from the control arm with each patient of the experimental arm.
Trial sites (1)
Facility
City
Region
Status
Department of Rheumatology and Immunology, Inselspital, University of Bern
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
